Collegium Pharmaceutical (NASDAQ:COLL) Upgraded at Zacks Research

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “strong-buy” rating in a report issued on Thursday, Zacks reports.

Several other research analysts have also recently weighed in on the stock. Oppenheimer initiated coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 price target on the stock. Truist Financial began coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 9th. They set a “buy” rating and a $49.00 price objective for the company. Piper Sandler reaffirmed a “neutral” rating and set a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 7th. Needham & Company LLC decreased their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Finally, Barclays dropped their price target on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.71.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded up $0.01 on Thursday, hitting $23.19. 558,644 shares of the company were exchanged, compared to its average volume of 831,925. The stock has a market capitalization of $755.07 million, a price-to-earnings ratio of 18.70, a price-to-earnings-growth ratio of 0.72 and a beta of 0.73. The company has a 50-day moving average price of $24.07 and a 200 day moving average price of $30.84. Collegium Pharmaceutical has a 1-year low of $21.43 and a 1-year high of $50.79. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The business’s revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.68 earnings per share. As a group, sell-side analysts predict that Collegium Pharmaceutical will post 6.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd lifted its position in shares of Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 427 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 418 shares in the last quarter. Assetmark Inc. boosted its position in Collegium Pharmaceutical by 9.3% in the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 335 shares during the period. EverSource Wealth Advisors LLC boosted its position in Collegium Pharmaceutical by 20.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company’s stock valued at $167,000 after buying an additional 861 shares during the period. Finally, Allworth Financial LP purchased a new position in Collegium Pharmaceutical in the 2nd quarter valued at approximately $175,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.

Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation.